Search Results
Feb 06, 2026, 15:00 ET LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC STROKE
"LT3001 showed potential benefit beyond the conventional thrombolytic time window, supporting its use in patients ineligible for IV thrombolysis or EVT, a population with high unmet need. The consistency of results across two independent trials, using different selection strategies, strengthens our confidence
More news about: Lumosa Therapeutics Co., Ltd.
Feb 06, 2026, 15:00 ET LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC STROKE
"LT3001 showed potential benefit beyond the conventional thrombolytic time window, supporting its use in patients ineligible for IV thrombolysis or EVT, a population with high unmet need. The consistency of results across two independent trials, using different selection strategies, strengthens our confidence
More news about: Lumosa Therapeutics Co., Ltd.
Jan 30, 2026, 08:00 ET Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy
More news about: Kazia Therapeutics Limited
Jan 27, 2026, 08:00 ET Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy
More news about: Kazia Therapeutics Limited
Jan 08, 2026, 09:00 ET Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
underway evaluating paxalisib in combination with checkpoint inhibition and chemotherapy for patients with advanced triple-negative breast cancer. EVT801, a selective VEGFR3 inhibitor, is currently in a Phase 1 clinical trial for advanced solid tumors. Kazia is working to rapidly progress these assets
More news about: Kazia Therapeutics Limited
Jan 06, 2026, 12:03 ET Espervita's EVT0185 Demonstrates Reversal of Metabolic Dysfunction and Liver Fibrosis in Cell Metabolism Publication
targeted metabolic reprogramming therapies. The company's lead compound, EVT0185, is a first-in-class inhibitor of acetyl-CoA metabolic enzymes that are responsible for the production and utilization of cytosolic acetyl-CoA. EVT0185 was previously reported in
More news about: Espervita Therapeutics, Inc.
Dec 10, 2025, 08:00 ET Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy
More news about: Kazia Therapeutics Limited
Dec 02, 2025, 18:30 ET Brainomix Announces New Study Published in Lancet Digital Health Demonstrating Impact of Brainomix 360 Stroke to Increase Endovascular Thrombectomy Rates
using Brainomix 360 Stroke (evaluation sites) saw a 100% increase in EVT, compared with a 63% increase at non-evaluation sites.At the level of the individual patient, the use of AI stroke software was associated with an increased likelihood of EVT compared with patients for whom AI software was not used
More news about: Brainomix
Dec 02, 2025, 09:00 ET Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
underway evaluating paxalisib in combination with checkpoint inhibition and chemotherapy for patients with advanced triple-negative breast cancer. EVT801, a selective VEGFR3 inhibitor, is currently in a Phase 1 clinical trial for advanced solid tumors. Kazia is working to rapidly progress these assets
More news about: Kazia Therapeutics Limited
Nov 18, 2025, 16:15 ET Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy
More news about: Kazia Therapeutics Limited
Oct 27, 2025, 07:15 ET Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy
More news about: Kazia Therapeutics Limited
Oct 21, 2025, 08:30 ET Revalesio to Present RNS60 <12-Hour Data from the Phase 2 RESCUE Trial in Acute Ischemic Stroke at World Stroke Congress 2025
patients enrolled within 12 hours of stroke onset and shows the potential of RNS60 to improve outcomes when combined with endovascular thrombectomy (EVT). Session Details
More news about: Revalesio Corporation
Oct 07, 2025, 08:30 ET Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy
More news about: Kazia Therapeutics Limited
Oct 02, 2025, 08:30 ET Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy
More news about: Kazia Therapeutics Limited
Oct 01, 2025, 09:21 ET Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence
More news about: Kazia Therapeutics Limited
Sep 16, 2025, 09:00 ET Telit Cinterion SE869eK5-DR GNSS Module Delivers Location Reliability and Accuracy With Untethered Dead Reckoning
trackers with seamless, dependable access to positioning information, even underground or amid jamming." SE869eK5-DR engineering validation testing (EVT) samples are available now, with design validation testing (DVT) samples scheduled for November. Visit the Telit Cinterion booth (E314) at
More news about: Telit Cinterion